Korean J Med.
2010 Jan;78(1):132-137.
Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate
- Affiliations
-
- 1Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. rhmrhm@cu.ac.kr
Abstract
- Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Three cases of Philadelphia (Ph) chromosome positive acute myeloid leukemia (AML) treated with imatinib mesylate (Glivec, STI571) and allogeneic hematopoietic stem cell transplantation after induction chemotherapy
- Complete Remission by Imatinib Mesylate (Glivec) in a Child Relapsing with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph (+) ALL) after Unrelated Donor Stem Cell Transplantation
- Complete Hematologic Response and Cytogenetic Remission after Imatinib and Dexamethasone Treatment of a Ph+ Precursor B-cell Acute Lymphoblastic Leukemia in Renal Transplantation Patient
- A Case of Drug Eruption with Localized ExfoliativeDermatitis Induced by Imatinib Mesylate
- A case of chronic myeloid leukemia with features of essential thrombocythemia in peripheral blood and bone marrow
